These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32448762)

  • 1. Role of Neutralizing Antibodies in CMV Infection: Implications for New Therapeutic Approaches.
    Sandonís V; García-Ríos E; McConnell MJ; Pérez-Romero P
    Trends Microbiol; 2020 Nov; 28(11):900-912. PubMed ID: 32448762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
    John S; Yuzhakov O; Woods A; Deterling J; Hassett K; Shaw CA; Ciaramella G
    Vaccine; 2018 Mar; 36(12):1689-1699. PubMed ID: 29456015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
    Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
    J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?
    Ohlin M
    Mol Immunol; 2014 Aug; 60(2):95-102. PubMed ID: 24802891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting.
    Giménez E; Blanco-Lobo P; Muñoz-Cobo B; Solano C; Amat P; Pérez-Romero P; Navarro D
    J Gen Virol; 2015 Sep; 96(9):2822-2831. PubMed ID: 26025872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.
    Gardner TJ; Bolovan-Fritts C; Teng MW; Redmann V; Kraus TA; Sperling R; Moran T; Britt W; Weinberger LS; Tortorella D
    Clin Vaccine Immunol; 2013 Apr; 20(4):540-50. PubMed ID: 23389931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
    Adler SP; Lewis N; Conlon A; Christiansen MP; Al-Ibrahim M; Rupp R; Fu TM; Bautista O; Tang H; Wang D; Fisher A; Culp T; Das R; Beck K; Tamms G; Musey L;
    J Infect Dis; 2019 Jul; 220(3):411-419. PubMed ID: 31535143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection.
    van Zanten J; van der Giessen M; van der Voort LH; van Son WJ; van der Bij W; The TH
    Clin Exp Immunol; 1991 Jan; 83(1):102-7. PubMed ID: 1846328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions.
    Manley K; Anderson J; Yang F; Szustakowski J; Oakeley EJ; Compton T; Feire AL
    Cell Host Microbe; 2011 Sep; 10(3):197-209. PubMed ID: 21925108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing activity of saliva against cytomegalovirus.
    Saccoccio FM; Gallagher MK; Adler SP; McVoy MA
    Clin Vaccine Immunol; 2011 Sep; 18(9):1536-42. PubMed ID: 21795465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding and neutralizing anti-cytomegalovirus activities in immune globulin products.
    Wang X; Xu Y; Scott DE; Murata H; Struble EB
    Biologicals; 2017 Nov; 50():35-41. PubMed ID: 29029807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.
    Deere JD; Chang WLW; Villalobos A; Schmidt KA; Deshpande A; Castillo LD; Fike J; Walter MR; Barry PA; Hartigan-O'Connor DJ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):13036-13041. PubMed ID: 31189602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice.
    Mancebo FJ; Nuévalos M; Lalchandani J; Martín Galiano AJ; Fernández-Ruiz M; Aguado JM; García-Ríos E; Pérez-Romero P
    Antiviral Res; 2024 Jul; 227():105914. PubMed ID: 38759930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors.
    Ishibashi K; Tokumoto T; Shirakawa H; Hashimoto K; Ikuta K; Kushida N; Yanagida T; Shishido K; Aikawa K; Toma H; Inoue N; Yamaguchi O; Tanabe K; Suzutani T
    Transpl Infect Dis; 2011 Jun; 13(3):318-23. PubMed ID: 20804536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection in patients with solid-organ transplant. Recently reviewed immunologic response and pathogenicity mechanisms.
    Caltenco-Serrano R; Sánchez-Huerta JL; Vargas-Jiménez R; Rodríguez-Suárez RS; Gómez-Barreto D
    Rev Latinoam Microbiol; 2001; 43(4):177-82. PubMed ID: 17061506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.
    Gardner TJ; Tortorella D
    Microbiol Mol Biol Rev; 2016 Sep; 80(3):663-77. PubMed ID: 27307580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dimerized single-chain variable fragment system for the assessment of neutralizing activity of phage display-selected antibody fragments specific for cytomegalovirus.
    Carlsson F; Trilling M; Perez F; Ohlin M
    J Immunol Methods; 2012 Feb; 376(1-2):69-78. PubMed ID: 22154743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.